BofA Securities lowered the price target for the Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock from “a Buy” to “a Neutral”. The rating was released on May 08, 2024, according to finviz. We previously noted in another research note published on December 19, 2023 by Morgan Stanley that upgraded the stock from an Equal-weight to an Overweight with a price target of $55 for RYTM stock. The research report from BofA Securities has upgraded the stock from Neutral to Buy, with a price target set at $27. The stock was resumed by Canaccord Genuity, who disclosed in a research note on January 18, 2023, to Buy and set the price objective to $52. In their research brief published August 08, 2022, Goldman analysts upgraded the Rhythm Pharmaceuticals Inc. stock from Neutral to Buy with a price target of $28.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 0.33% within the last five trades and 16.33% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -9.37% in the last 6 months and -0.02% was subtracted to its value over the previous 3 months. RYTM stock is trading at a margin of 4.88%, 7.53% and 14.06% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Sponsored
As of the close of trading, RYTM deals in the Healthcare domain. The stock is trading -18.83 percent below its 52-week high and 175.29 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 90.35. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Rhythm Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -295.57 percent and the profit margin is -297.91 percent, and the company has reported a gross margin of 87.45 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $2.60 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 28.30 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 42.24, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 10.51 percent of Rhythm Pharmaceuticals Inc. shares are owned by insiders, and 101.91 percent are held by financial institutions. Shulman Joseph, the Chief Technical Officer at Rhythm Pharmaceuticals Inc. (RYTM) has sold 3,984 shares of firm on May 09 ’24 at a price of $38.47 against the total amount of $0.15 million. In another inside trade, German Christopher Paul, Corporate Controller & CAO of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) sold 368 shares of the firm on Apr 02 ’24 for a total worth of $15368.0 at a price of $41.76. An inside trade which took place on Mar 21 ’24, Chief Technical Officer of Rhythm Pharmaceuticals Inc. Shulman Joseph sold 18,235 shares of firm against total price of $0.74 million at the cost of $40.34 per share.
